在治疗FGFR2-驱动的胃癌的临床发展和挑战
David K Lau1,2,3,4, Jack P Collin1,2, John M Mariadason1,2
1Olivia Newton-John Cancer Research Institute, Heidelberg, VIC 3084, Australia.
Biomedicines
|May 25, 2024
概括
胃癌 (GC) 仍然是致命的,但FGFR2放大呈现了一个目标. 本综述探讨了针对FGFR2的治疗方法,包括抑制剂和PROTACs,用于治疗晚期GC.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药物开发 药物开发
背景情况:
- 转移性胃癌 (GC) 尽管在治疗方面取得了进展,但其存活率很差.
- 异常的FGFR2信号传递,通常是由于FGFR2放大,在3-11%的GC中发现.
- 目前,没有批准的疗法专门针对GC中的FGFR2.
研究的目的:
- 审查FGFR2作为GC治疗点的重要性.
- 检查FGFR2定向治疗的临床前和临床数据.
- 讨论开发针对GC的FGFR2向治疗的挑战和机会.
主要方法:
- 临床前和临床研究的文献综述.
- 对胃癌中的FGFR2放大数据的分析.
- 对针对FGFR的各种治疗策略的评估2.
主要成果:
- 在GC患者的一个子集中,FGFR2放大是关键驱动因素.
- 小分子抑制剂,基于抗体的疗法和PROTACs对FGFR2向有希望.
- 针对GC的FGFR2导向疗法的临床开发正在进行中.
结论:
- 对于GC治疗,FGFR2是一个重要的可操作的目标.
- 目前正在研究多种治疗方式,以向GC中的FGFR2.
- 进一步的临床开发对于克服挑战和实现FGFR2向疗法的潜力至关重要.
更多相关视频
06:21Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer
Published on: May 10, 2024
674
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
7.2K
相关概念视频
02:57Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
02:38Mitogens and the Cell Cycle
6.5K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K